Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
With inhibition of p38, ERK, and JNK, the TSP-2-induced cell migration and MMP-2 expression were abolished, indicating that the TSP-2's effect on PCa is MAPK dependent.
|
28122633 |
2017 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used the human, androgen-sensitive prostate carcinoma cell line LNCaP in coculture with the human osteosarcoma cell line OHS to experimentally address the possibility of androgen-dependent regulatory effects on the functional MT1-MMP/TIMP-2/MMP-2 complex upon interaction between prostate carcinoma and osteoblastic cells in metastasis of prostate cancer to bone.
|
14598888 |
2003 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We showed, to our knowledge for the first time, that genistein treatment, compared with no treatment, was associated with decreased levels of MMP-2 transcripts in normal prostate cells from prostate cancer-containing tissue.
|
19638505 |
2009 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have demonstrated that MMP-2 and its regulators are underexpressed in PCa.
|
22555040 |
2013 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, we concluded that silencing of LASS2/TMSG1 may promote invasion of prostate cancer cell in vitro through increase of V-ATPase activity and extracellular hydrogen ion concentration and in turn the activation of secreted MMP-2.
|
22573553 |
2012 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study shows that silibinin could inhibit the invasion, motility and migration of ARCaP(M) cells via down-regulation of vimentin and MMP-2 and therefore may be a promising agent against prostate cancer bone metastasis.
|
19578386 |
2009 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that both MAPKAPK2 and HSP27 are necessary for TGFbeta-mediated increases in MMP-2 and cell invasion in human prostate cancer.
|
16407830 |
2006 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicated that hCGβ induced cell motility via promoting ERK1/2 phosphorylation and MMP-2 upregulation in human prostate cancer DU145 cells.
|
23424616 |
2013 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There were no differences in activities of MMP-2, proMMP-9, and MMP-9/NGAL (neutrophil gelatinase associated lipocalin) complex (gelatin substrate) in men with detected prostate cancer, although the latter two were somewhat diminished.
|
29175302 |
2017 |
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to determine the association between MMP2 polymorphism and the risk of prostate cancer in Iranian men.
|
27541146 |
2017 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overexpression of KLF2 inhibited the migration and invasion of PCa cells via the suppression of MMP2.This study demonstrates that KLF2 might act as a tumor suppressor gene in PCa and that the pharmaceutical upregulation of KLF2 may be a potential approach for treatment.
|
30520325 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The higher concentration of MMP-9 as well as the increased ratios of MMP-2 and MMP-9 to TIMP-1 in malignant tissue prove the proteolytic dysbalance in prostate cancer, which does not seem to be associated with the stage and grade of the tumor.
|
12361907 |
2002 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate the expression of LRP-1, MMP-2 and MMP-9 across various grades of prostatic diseases as benign prostatic hyperplasia (BPH), BPH plus prostatitis (BPH+P), high grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer (PCa).
|
27931798 |
2017 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sphere formation and side population assays suggested that miR-1301-3p promoted the expansion of prostate cancer stem cells, and increased the expression of prostate cancer stem cell-associated genes, such as OCT4, SOX2, NANOG, CD44, KLF4, c-MYC, and MMP2.
|
29358129 |
2018 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Silencing of LASS2/TMSG1 gene in PC-3M-2B4 cells increased V-ATPase activity, extracellular hydrogen ion concentration and in turn the activation of secreted MMP-2 and MMP-9, which coincided with enhancing cell proliferation, cell survival, and cell invasion in vitro, as well as acceleration of prostate cancer (PCA) growth and lymph node metastases in vivo.
|
24453046 |
2014 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Silencing of filamin C increased the expression of matrix metallopeptidase 2 and improved the metastasis of prostate cancer in a zebrafish model.
|
25577646 |
2015 |
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with MMP2 (-1306) CT genotype as well as T allele were at higher risk of PCa (p = 0.018; OR = 1.68 and p = 0.015; OR = 1.52).
|
22374248 |
2012 |
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study indicates MMP2-1306 C/T polymorphism might increase PCa risk, particularly for Asian population.
|
28445160 |
2017 |
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results indicated that MMP2 polymorphism had no role in the vascular invasion of PCa.
|
26319608 |
2015 |
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results illustrate the potential use of MMP2 SNP as a molecular marker for prostate cancer.
|
19117773 |
2011 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data showed that knockdown of SPAG9 in prostate cancer cell lines inhibited cell motility and invasion due to the inactivation of metalloproteinase-2 (MMP‑2)/MMP-9 by upregulation of tissue inhibitor of metalloproteinase-1 (TIMP-1)/TIMP-2.
|
25310386 |
2014 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MT1-MMP and its substrates pro-MMP-2 and pro-MMP-9 are often overexpressed in a variety of cancers including prostate cancer and the expression levels correlate with the grade of malignancy in prostate cancer cells.
|
21219645 |
2011 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we demonstrated that RUNX3 overexpression inhibited prostate cancer cell migration and invasion resulting from the elevated upregulation of tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), which subsequently inhibited metalloproteinase-2 (MMP-2) expression and activity in vitro.
|
24475196 |
2014 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, there was a significant difference in the ratio of the active form (62 kDa) and proform (72 kDa) of MMP-2 among normal, BPH and prostate cancer tissues.
|
15356679 |
2004 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover we also demonstrate that visfatin promotes the expression and activity of MMP-2/9 which are important proteases involved in the breakdown of the extracellular matrix, suggesting a possible role for visfatin in prostate cancer metastases.
|
19819277 |
2010 |